Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01050790 · OUTCOME

CTA Expression Before and After Azacitidine Therapy

Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma · Source last updated 2018-06-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
3 months

What was measured

Six patients tested have demonstrated CTA up-regulation in either unfractionated bone marrow (n = 4) or CD138+ cells (n = 2). CTA (CTAG1B)-specific T cell response has been observed in all three patients tested and persists following SCT.

Groups in this outcome

5-azacytidine + Lenalidomide -> Auto Stem Cell Transplant

azacitidine: 75 mg/sq m daily for 5 days lenalidomide: 10 mg p.o. daily, Days 6-21

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
5-azacytidine + Lenalidomide -> Auto Stem Cell Transplant17

Reported measurements

CTA up-regulation
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
5-azacytidine + Lenalidomide -> Auto Stem Cell Transplant6Not reportedNot reportedNot reportedNot reported
CD138+ cells
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
5-azacytidine + Lenalidomide -> Auto Stem Cell Transplant2Not reportedNot reportedNot reportedNot reported
unfractionated bone marrow
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
5-azacytidine + Lenalidomide -> Auto Stem Cell Transplant4Not reportedNot reportedNot reportedNot reported
CTA (CTAG1B)-specific T cell response
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
5-azacytidine + Lenalidomide -> Auto Stem Cell Transplant3Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        6
    title
    CTA up-regulation
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        2
    title
    CD138+ cells
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        4
    title
    unfractionated bone marrow
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        3
    title
    CTA (CTAG1B)-specific T cell response
denoms
  1. counts
    1. group Id
      OG000
      value
      17
    units
    Participants
description
Six patients tested have demonstrated CTA up-regulation in either unfractionated bone marrow (n = 4) or CD138+ cells (n = 2). CTA (CTAG1B)-specific T cell response has been observed in all three patients tested and persists following SCT.
groups
  1. description
    azacitidine: 75 mg/sq m daily for 5 days lenalidomide: 10 mg p.o. daily, Days 6-21
    id
    OG000
    title
    5-azacytidine + Lenalidomide -> Auto Stem Cell Transplant
param Type
NUMBER
reporting Status
POSTED
time Frame
3 months
title
CTA Expression Before and After Azacitidine Therapy
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice